newsroom /

Milan, Italy Mar. 22, 2022

KLISBio to disclose state-of-the-art tissue-engineered technology platform at 2022 CG Musculoskeletal Conference

Milan, Italy (March 22, 2022) – Today, KLISBio, a MedTech company challenging the status quo in regenerative medicine by leveraging a silk-based multidisciplinary technology platform, announced its attendance to 2022 CG Musculoskeletal Conference. Ahead of the American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting March 22-26, 2022 in Chicago, Canaccord Genuity will host its CG Musculoskeletal Conference March 22, 2022 in Chicago – IL. KLISBio’s designated attendee to 2022 CG Musculoskeletal Conference is Jason Schense, CBO and COO.

Among the best innovators in orthopedics, biologics and regenerative medicine participating in CG Musculoskeletal Conference, KLISBio is open to expand its network and build strong relations with investors and industry leaders, in the attempt to move forward the current standard of care in peripheral nerve repair with SILKBridge, KLISBio’s first product in pipeline for peripheral nerve repair.

SILKBridge is an absorbable medical device made of Bombyx mori silk fibroin and is intended for the surgical repair of peripheral nerve discontinuities to support regeneration across the defect. SILKBridge is expected to be available for clinical use in the US market in 2023.The tissue engineered technology at the core of SILKBridge merges a deep-rooted cultural tradition and know-how in silk handling with the most advanced technologies creating a highly purified material required for biomedical applications, without the need for chemical cross-linking reactions that alter silk fibroin.

KLISBio is focused on developing innovative solutions that solve prominent unmet clinical needs through a silk-based multidisciplinary technology platform able to generate products and solutions for a variety of clinical indications, such as peripheral nerve injuries, peripheral vascular diseases, bone defects, tendon tears and situations where a sustained drug release is needed.

“KLISBio has developed a versatile technology platform with the aim to rethink the way tissue engineering is performed, offering new solutions and leveraging pure silk fibroin as biocompatible material.”, said Jason Schense, CBO and COO.

KLISBio is powered by an international group of world leaders in MedTech including Grecchi, CEO; Antonio Alessandrino, President & Chief Technology Officer; Giuliano Freddi, Chief Scientific Officer; Jason Schense, Chief Business Officer and Chief Operating Officer. The company recently announced that Rodrigo Bianchi will serve as Chairman of the Board, coming to KLISBio with more than three decades’ experience in global healthcare.

In addition to the strong leadership team, KLISBio works with physicians, engineers, researchers, chemists and biologists worldwide who represent excellence in the biomedical space. The company holds patents in Silk regenerated Fibroin + Native Silk Fibroin Pairing, Silk-based Composites and Core-Shell Silk Nanofibers.

About KLISBio:

KLISBio is a clinical-stage regenerative medicine company focused on developing innovative technology platforms entirely based on natural silk fibroin. The company, headquatered in Milan, Italy, currently has several assets under development, such as vascular graft, bone graft substitutes and rotator cuff repair.